Phentermine

(Pondimin is the brand name for fenfluramine and Redux is the brand name for dexfenfluramine).

In 1997 Fen phen and Redux were taken off the market by Wyeth, the manufacturer, after it was discovered that using these drugs in combination led to serious cardiovascular side effects, including Primary Pulmonary Hypertension (PPH).

PPH is a rare blood vessel disorder in which blood pressure in the pulmonary artery connecting the heart to the lungs rises to dangerously high levels. PPH is sometimes fatal.

Investigations conducted by the Mayo Clinic found 24 cases of heart valve disease in patients treated with the combination of phentermine and Pondimin (fen-phen). Another study found that of 291 patients who had been treated with Pondimin or Redux, usually in combination with phentermine, nearly 1/3 showed abnormal echocardiograms.

If you feel you qualify for damages or remedies that might be awarded in a possible class action against Phentermine, please click the link below to submit your complaint.